The successful application of honey in wound care management has been achieved due to honey’s potent antibacterial effects, characterised by its multifactorial action. Impressive clinical efficacy has ignited its further use in diverse clinical disciplines, including stomatology. Indeed, there is increasing usage of honey in dental medicine as a preventive or therapeutic remedy for some periodontal diseases mainly associated with bacteria, such as dental caries, gingivitis and mucositides. Dental caries is undoubtedly a major oral health problem worldwide, with an increasing tendency of incidence. The purpose of this perspective review is to describe the recent progress in the laboratory and clinical use of honey in the prevention of dental caries, with emphasis on the antibacterial and antibiofilm effects of honey. The role of honey in the cariogenic process is also discussed. In addition, the quality of honey and the urgent in vitro evaluation of its antibacterial/antibiofilm properties before clinical use are highlighted. Findings based on data extracted from laboratory studies demonstrate the pronounced antibacterial effect of different honeys against a number of periodontal pathogens, including Streptococcus mutans. Although the promising antibiofilm effects of honey have been reported mainly against S. mutans, these results are limited to very few studies. From a clinical point of view, honey significantly reduces dental plaque; however, it is not superior to the conventional agent. Despite the positive in vitro results, the clinical effectiveness of honey in the prevention of dental caries remains inconclusive since further robust clinical studies are needed.
Herpes simplex virus type 1 (HSV-1) is a leading cause of infectious blindness worldwide. Most of the initial infection cases manifest as acute epithelial keratitis. Reactivation of herpesviruses is common in critically ill patients, including patients with severe Coronavirus disease (COVID-19). However, the data on COVID-19-related ocular infections is sparse, despite recent observations that more than 30% of COVID-19-infected patients had ocular manifestations. We report five cases of HSV-1 keratitis in COVID-19 patients. In total, five COVID-19 patients underwent ophthalmic examination, showing similar symptoms, including photophobia, tearing, decreased vision, eye redness, and pain. After initial assessment, tests of visual acuity and corneal sensitivity, a fluorescein staining test, and complete anterior and posterior segment examinations were performed. A diagnosis of HSV-1 keratitis was confirmed in all cases. Therapy was initiated using a local and systemic antiviral approach together with local antibiotic and mydriatic therapy. The complete reduction of keratitis symptoms and a clear cornea was achieved in all patients within 2 weeks. SARS-CoV-2 infection may be a risk factor for developing HSV-1 keratitis, or it may act as a potential activator of this ocular disease.
1 August 2023 in Journal of Electrical Engineering
Glaucomatous changes of the optic nerve head could be detected from fundus images. Focusing on optic nerve head appearance, and its difference from healthy images, altogether with the availability of plenty of such images in public fundus image databases, these images are ideal sources for artificial intelligence methods applications. In this work, we used ensemble learning methods and compared them with various single CNN models (VGG-16, ResNet-50, and MobileNet). The models were trained on images from REFUGE public dataset. The average voting ensemble method outperformed all mentioned models with 0.98 accuracy. In the AUC metric, the average voting ensemble method outperformed VGG-16 and MobileNet models, which had significantly weaker performance when used alone. The best results were observed using the ResNet-50 model. These results confirmed the significant potential of ensemble learning in enhancing the overall predictive performance in glaucomatous changes detection, but the overall performance could be negatively affected when models with weaker prediction performance are included.
Introduction This study was performed to compare the efficacy and safety of PreserFlo MicroShunt (PMS) implantation with mitomycin C (MMC) applied by sub-tenon injection versus conventional application by MMC-soaked sponges. Methods This retrospective, 1-year cohort study included 100 eyes of 100 patients with glaucoma who underwent PMS implantation with MMC (0.4 mg/ml) delivered either by sub-tenon injection (50 eyes) or via soaked sponges (50 eyes). The primary outcome measure at 1 year was intraocular pressure (IOP) reduction, with complete success defined as an IOP reduction of ≥ 20% and achieving a target IOP of ≤ 21 or 18 mmHg without the use of medication. Secondary outcomes, including corneal endothelial cell density (CECD) loss, the number of medications, and complications, were assessed and compared between the groups. Results Sustained reductions in mean IOP were observed in both groups over the 1-year follow-up, with no significant differences between the groups. The complete success rate, with a target IOP of ≤ 21 mmHg after 1 year, was 19.3% in the sponge group and 26.4% in the injection group. The qualified success rate was 59.0% and 87.4% in the sponge and injection groups, respectively. A longer survival rate was observed in the injection group than in the sponge group when IOP was below 21 mmHg. The mean CECD significantly decreased (P < 0.01) from baseline to each postoperative follow-up time point in both groups. At 1 year postoperatively, the percentage of total CECD loss was 8.1% in the sponge group and 8.0% in the injection group. However, no significant differences in mean CECD values, the number of medications, or adverse events were found between the groups. Conclusions PMS implantation with sub-tenon injection of MMC was comparable in terms of efficacy and safety to traditional MMC delivery via soaked sponges. However, the injection group demonstrated a significantly higher success rate than the sponge group.
1 December 2023 in Journal of Electrical Engineering
Reconstruction of a 3D eye model by photogrammetry from a smartphone video could be prospectively used in self-diagnosis, screening and telemedicine monitoring of diseases of the front part of the eye and its surroundings. The main use could be found in the treatment of diseases of the curvature and surface of the cornea and in follow-up after some refractive procedures. In our work, we create 3D image-based models of the eye after scanning the face with a smartphone. An unexpected phenomenon appeared during the reconstruction of the transparent cornea – a crater-like depression was formed at the place where nearby objects reflected on the cornea, which corresponds to the first Purkinje image, the so-called glint. We thus encountered complications that may arise when modelling transparent living structures from a video taken in a normal environment, which will need to be solved if we want to create such 3D models of the eye using this method for medical purposes. Another 3D reconstruction approach or additional algorithms must be considered as a future work.
Background: Visual impairment and blindness significantly affect patient health and socioeconomic status. Among the main causes of vision impairment are Age-related Macular Degeneration (AMD) in both wet (neovascular) and dry (non-exudative) forms, and Diabetic Macular Edema (DME). These conditions represent major healthcare burdens due to associated medical and societal costs. Objective: The objective of the present study was to evaluate the economic burden of wet and dry AMD and DME in Slovakia, emphasizing direct medical and non-medical costs, as well as indirect costs due to lost productivity. Methods: A prevalence-based "cost-of-illness" strategy was applied retrospectively for the year 2021 from a societal perspective. Data were collected using structured questionnaires from patients and ophthalmologists, Slovak healthcare databases (National Centre for Health Information—NCZI), health insurance records, and patient advocacy groups. Bottom-up costing was applied to direct healthcare costs, establishing healthcare services and unit costs, whereas indirect costs were ascertained by the human capital approach. Non-medical costs were also extrapolated from patient surveys and consultant interviews. Results: For the year 2021, the total annual economic burden for wet AMD was approximately €105.7 million and for DME was €45.1 million in Slovakia. The total annual cost per patient was €5,281 for wet AMD and €4,049 for DME. Direct healthcare costs represented over half (54%) of wet AMD costs, predominantly due to pharmacotherapy (€23.9 million) and hospital/emergency care (€13.7 million). For DME, direct care consisted of approximately 36% (€16.0 million), with pharmacotherapy (€6.2 million) and treatment monitoring and management (€2.5 million each) as the leaders. Non-medical direct spending (transport, home adaptation) was negligible for both conditions (13% wet AMD, 2% DME). Indirect costs like absenteeism, presenteeism, and formal care accounted for 33% of wet AMD and over 60% of the cost of DME. Specifically, presenteeism was the largest share in indirect costs in DME (€16.1 million). Conclusion: Wet AMD and DME impose tremendous economic loads on the Slovak healthcare system and society, which are predominantly driven by direct medical and indirect productivity costs. Effective prevention, early diagnosis, and optimal management strategies would significantly reduce these economic loads and improve patient outcomes.